Literature DB >> 7586980

Osteoporosis in rheumatoid arthritis: effect of disease activity.

R Celiker1, Y Gökçe-Kutsal, A Cindas, M Ariyürek, N Renda, Z Koray, O Basgöze.   

Abstract

In addition to juxtaarticular osteoporosis, which appears to reflect predominantly local disease mechanisms, more generalized bone loss can occur in rheumatoid arthritis (RA). The aim of this study was to compare bone mineral density (BMD) of the lumbar spine and proximal femur in RA patients versus controls and evaluate the influence of disease related determinants. Twenty-seven patients with RA and twenty healthy subjects were included in this study. BMD was significantly reduced in RA patients compared with the control group. BMD was correlated with duration of disease, health assessment questionnaire scores, hand grip strength and erythrocyte sedimentation rate. These results support the hypothesis that BMD may be affected by RA related determinants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586980     DOI: 10.1007/BF02207677

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

Review 1.  Bone mass in patients with rheumatoid arthritis.

Authors:  R F Laan; P L van Riel; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

2.  Therapeutic criteria in rheumatoid arthritis.

Authors:  O STEINBROCKER; C H TRAEGER; R C BATTERMAN
Journal:  J Am Med Assoc       Date:  1949-06-25

3.  Bone densitometry.

Authors:  J D Adachi; P Colton
Journal:  J Rheumatol       Date:  1990-04       Impact factor: 4.666

4.  Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids.

Authors:  A Verstraeten; J Dequeker
Journal:  Ann Rheum Dis       Date:  1986-10       Impact factor: 19.103

5.  Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis. Effects of low-dose corticosteroids.

Authors:  M J Garton; D M Reid
Journal:  Arthritis Rheum       Date:  1993-02

6.  Serum osteocalcin and calcitropic hormones in a homogeneous group of patients with rheumatoid arthritis: its implication in the osteopenia of the disease.

Authors:  H Rico; M Revilla; M Alvarez de Buergo; L F Villa
Journal:  Clin Exp Rheumatol       Date:  1993 Jan-Feb       Impact factor: 4.473

7.  Spinal trabecular bone mineral content in patients with non-steroid treated rheumatoid arthritis.

Authors:  J E Compston; E O Crawley; C Evans; M M O'Sullivan
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

8.  Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis.

Authors:  A K Gough; N F Peel; R Eastell; R L Holder; J Lilley; P Emery
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

9.  Predictors of fractures in early rheumatoid arthritis.

Authors:  B A Michel; D A Bloch; J F Fries
Journal:  J Rheumatol       Date:  1991-06       Impact factor: 4.666

10.  Vertebral osteoporosis in rheumatoid arthritis patients: effect of low dose prednisone therapy.

Authors:  R F Laan; P L van Riel; L J van Erning; J A Lemmens; S H Ruijs; L B van de Putte
Journal:  Br J Rheumatol       Date:  1992-02
View more
  11 in total

1.  Bone mineral density in children with juvenile chronic arthritis.

Authors:  A Cetin; R Celiker; F Dinçer; M Ariyürek
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

2.  Digital radiogrammetry as a new diagnostic tool for estimation of disease-related osteoporosis in rheumatoid arthritis compared with pQCT.

Authors:  J Böttcher; A Pfeil; B Heinrich; G Lehmann; A Petrovitch; A Hansch; J P Heyne; H J Mentzel; A Malich; G Hein; W A Kaiser
Journal:  Rheumatol Int       Date:  2005-03-11       Impact factor: 2.631

3.  The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.

Authors:  Funda Tascioglu; Omer Colak; Onur Armagan; Ozkan Alatas; Cengiz Oner
Journal:  Rheumatol Int       Date:  2005-02-02       Impact factor: 2.631

4.  Factors playing a role in the development of decreased bone mineral density in juvenile chronic arthritis.

Authors:  Reyhan Celiker; Serpil Bal; Aysin Bakkaloğlu; Eda Ozaydin; Turgay Coskun; Alp Cetin; Fitnat Dinçer
Journal:  Rheumatol Int       Date:  2003-03-12       Impact factor: 2.631

5.  Sustained maintenance of exercise induced muscle strength gains and normal bone mineral density in patients with early rheumatoid arthritis: a 5 year follow up.

Authors:  A Häkkinen; T Sokka; H Kautiainen; A Kotaniemi; P Hannonen
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

6.  The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis.

Authors:  Funda Tascioglu; Cengiz Oner; Onur Armagan
Journal:  Rheumatol Int       Date:  2003-03-21       Impact factor: 2.631

7.  Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.

Authors:  Kageyama Yasunori; Takahashi Masaaki; Nagafusa Tetsuyuki; Kobayashi Hayato; Nagano Akira
Journal:  Clin Rheumatol       Date:  2008-03-13       Impact factor: 2.980

Review 8.  Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.

Authors:  B F Ricciardi; J Paul; A Kim; L A Russell; J M Lane
Journal:  Osteoporos Int       Date:  2012-09-07       Impact factor: 4.507

9.  Bone loss. Quantitative imaging techniques for assessing bone mass in rheumatoid arthritis.

Authors:  C F Njeh; H K Genant
Journal:  Arthritis Res       Date:  2000-08-03

10.  The utility of clinical decision tools for diagnosing osteoporosis in postmenopausal women with rheumatoid arthritis.

Authors:  Caroline Brand; Adrian Lowe; Stephen Hall
Journal:  BMC Musculoskelet Disord       Date:  2008-01-29       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.